Compare IBRX & CENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IBRX | CENX |
|---|---|---|
| Founded | 2014 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Aluminum |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.7B |
| IPO Year | N/A | 1996 |
| Metric | IBRX | CENX |
|---|---|---|
| Price | $2.05 | $40.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $9.71 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 13.6M | 1.8M |
| Earning Date | 11-04-2025 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.83 |
| Revenue | $82,555,000.00 | ★ $2,525,100,000.00 |
| Revenue This Year | $667.18 | $15.66 |
| Revenue Next Year | $93.03 | $0.78 |
| P/E Ratio | ★ N/A | $46.98 |
| Revenue Growth | ★ 1025.95 | 20.15 |
| 52 Week Low | $1.83 | $13.05 |
| 52 Week High | $4.27 | $40.83 |
| Indicator | IBRX | CENX |
|---|---|---|
| Relative Strength Index (RSI) | 45.08 | 74.90 |
| Support Level | $1.95 | $38.53 |
| Resistance Level | $2.29 | $40.83 |
| Average True Range (ATR) | 0.12 | 1.61 |
| MACD | -0.02 | 0.56 |
| Stochastic Oscillator | 19.09 | 94.48 |
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
Century Aluminum Co produces primary aluminum standard grade and value-added products. The firm operates smelter facilities in the United States and Iceland. The majority of revenue is generated from Glencore, which agreed to purchase nearly all of Century Aluminum's North American production. Century purchases nearly all of its alumina from Glencore. The company produces high purity aluminum, standard-grade aluminum sow and tee bars, and value-added billet and foundry products. Century also owns a carbon anode production facility in the Netherlands.